| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Departments of Clinical Chemistry [J. B. d. K., R. W. R., D. W. S.], Experimental Urology [G. W. V., D. H., L. A. K., T. W. A., J. A. S.], and Epidemiology and Biostatistics [L. A. K.], University Medical Centre Nijmegen, 6500 HB Nijmegen, the Netherlands
We identified DD3PCA3 as one of the most prostate cancer-specific genes at present (M. J. Bussemakers et al. Cancer Res., 59: 5975–5979, 1999). Consequently, DD3PCA3 is an interesting candidate for use as a diagnostic and/or prognostic marker. In this study we developed a method for the accurate quantification of DD3PCA3 mRNA, using real-time quantitative reverse transcription-PCR. DD3PCA3 was expressed at low levels in normal prostate but not in 21 selected other normal tissues, blood, or 39 tumor samples other than prostate. The diagnostic and prognostic value of DD3PCA3 in normal, hyperplastic, and malignant prostate tissues was determined and compared with another promising tumor marker for prostate cancer, telomerase reverse transcriptase (hTERT gene), the expression of which is related to telomerase activity. Sensitivity and specificity estimates for both genes were calculated as the area under the receiver-operating characteristics curve (AUC-ROC). DD3PCA3 (AUC-ROC, 0.98) demonstrated better diagnostic efficacy than hTERT (AUC-ROC, 0.88). Moreover, the median increase in mRNA expression in tumor tissues compared with nonmalignant prostate tissues was much higher for DD3PCA3 (34-fold) than for hTERT (6-fold). In tumor tissues, the median expression of DD3PCA3 was much higher than hTERT (5849 versus 10 normalized mRNA copies). A significant relationship was observed only between tumor stage and hTERT gene expression. We conclude that expression of the DD3PCA3 gene is a very sensitive and specific marker for the detection of prostate tumor cells in a high background of normal (prostate) cells. Consequently, DD3 measurements may be used for clinical application in prostate needle biopsies or bodily fluids such as blood, ejaculate, urine, or prostate massage fluid.
This article has been cited by other articles:
|
|
 |
|
  J. E. Wilusz, H. Sunwoo, and D. L. Spector Long noncoding RNAs: functional surprises from the RNA world Genes & Dev., July 1, 2009; 23(13): 1494 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. H. Jansen, J. Krijgsveld, A. van Rijswijk, G.-J. van den Bemd, M. S. van den Berg, W. M. van Weerden, R. Willemsen, L. J. Dekker, T. M. Luider, and G. Jenster Exosomal Secretion of Cytoplasmic Prostate Cancer Xenograft-derived Proteins Mol. Cell. Proteomics, June 1, 2009; 8(6): 1192 - 1205. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Zheng, J. Sun, F. Wiklund, Z. Gao, P. Stattin, L. D. Purcell, H.-O. Adami, F.-C. Hsu, Y. Zhu, J. Adolfsson, et al. Genetic Variants and Family History Predict Prostate Cancer Similar to Prostate-Specific Antigen Clin. Cancer Res., February 1, 2009; 15(3): 1105 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Laxman, D. S. Morris, J. Yu, J. Siddiqui, J. Cao, R. Mehra, R. J. Lonigro, A. Tsodikov, J. T. Wei, S. A. Tomlins, et al. A First-Generation Multiplex Biomarker Analysis of Urine for the Early Detection of Prostate Cancer Cancer Res., February 1, 2008; 68(3): 645 - 649. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hessels, F. P. Smit, G. W. Verhaegh, J. A. Witjes, E. B. Cornel, and J. A. Schalken Detection of TMPRSS2-ERG Fusion Transcripts and Prostate Cancer Antigen 3 in Urinary Sediments May Improve Diagnosis of Prostate Cancer Clin. Cancer Res., September 1, 2007; 13(17): 5103 - 5108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. M. Thompson and D. P. Ankerst Prostate-specific antigen in the early detection of prostate cancer Can. Med. Assoc. J., June 19, 2007; 176(13): 1853 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P.M.Q. van Gils, D. Hessels, O. van Hooij, S. A. Jannink, W. P. Peelen, S. L.J. Hanssen, J. A. Witjes, E. B. Cornel, H. F.M. Karthaus, G. A.H.J. Smits, et al. The Time-Resolved Fluorescence-Based PCA3 Test on Urinary Sediments after Digital Rectal Examination; a Dutch Multicenter Validation of the Diagnostic Performance Clin. Cancer Res., February 1, 2007; 13(3): 939 - 943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. V. Prasanth and D. L. Spector Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum Genes & Dev., January 1, 2007; 21(1): 11 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Groskopf, S. M.J. Aubin, I. L. Deras, A. Blase, S. Bodrug, C. Clark, S. Brentano, J. Mathis, J. Pham, T. Meyer, et al. APTIMA PCA3 Molecular Urine Test: Development of a Method to Aid in the Diagnosis of Prostate Cancer Clin. Chem., June 1, 2006; 52(6): 1089 - 1095. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Thelen, J.-G. Scharf, P. Burfeind, B. Hemmerlein, W. Wuttke, B. Spengler, V. Christoffel, R.-H. Ringert, and D. Seidlova-Wuttke Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer Carcinogenesis, August 1, 2005; 26(8): 1360 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Foley, D. Hollywood, and M. Lawler Molecular pathology of prostate cancer: the key to identifying new biomarkers of disease Endocr. Relat. Cancer, September 1, 2004; 11(3): 477 - 488. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Zelivianski, R. Glowacki, and M.-F. Lin Transcriptional activation of the human prostatic acid phosphatase gene by NF-{kappa}B via a novel hexanucleotide-binding site Nucleic Acids Res., July 7, 2004; 32(12): 3566 - 3580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. O'Hara, J. G. Moreno, D. R. Zweitzig, S. Gross, L. G. Gomella, and L. W.M.M. Terstappen Multigene Reverse Transcription-PCR Profiling of Circulating Tumor Cells in Hormone-Refractory Prostate Cancer Clin. Chem., May 1, 2004; 50(5): 826 - 835. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Latil, I. Bieche, L. Chene, I. Laurendeau, P. Berthon, O. Cussenot, and M. Vidaud Gene Expression Profiling in Clinically Localized Prostate Cancer: A Four-Gene Expression Model Predicts Clinical Behavior Clin. Cancer Res., November 15, 2003; 9(15): 5477 - 5485. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gandini, M. Santulli, M. R. Cardillo, A. Stigliano, and V. Toscano Correspondence re: J. B. de Kok et al., DD3, A Very Sensitive and Specific Marker to Detect Prostate Tumors. Cancer Res., 62: 2695-2698, 2002. Cancer Res., August 1, 2003; 63(15): 4747 - 4747. [Full Text] [PDF]
|
|
|
|
|
|
G. W. Verhaegh, J. B. de Kok, D. Hessels, F. Smit, and J. A. Schalken Reply Cancer Res., August 1, 2003; 63(15): 4748 - 4749. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
